Evidence map›Paper›PMID 36092143›Full record

ArticleRSC medicinal chemistry2022

Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics.

Kenji Mishiro, Mengfei Wang, Saki Hirata, Takeshi Fuchigami, Kazuhiro Shiba, Seigo Kinuya, Kazuma Ogawa

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kenji MishiroInstitute for Frontier Science Initiative, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan kogawa@p.kanazawa-u.ac.jp.ORCID https://orcid.org/0000-0002-5071-7574
Mengfei WangGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan.
Saki HirataGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan.
Takeshi FuchigamiGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan.ORCID https://orcid.org/0000-0001-8141-1212
Kazuhiro ShibaResearch Center for Experimental Modeling of Human Disease, Kanazawa University Takara-machi Kanazawa Ishikawa 920-8640 Japan.
Seigo KinuyaDepartment of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University Takara-machi Kanazawa Ishikawa 920-8641 Japan.
Kazuma OgawaInstitute for Frontier Science Initiative, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan kogawa@p.kanazawa-u.ac.jp.ORCID https://orcid.org/0000-0002-1691-7302
Kanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As sigma receptors are highly expressed on various cancer cells, radiolabeled sigma receptor ligands have been developed as imaging and therapeutic probes for cancer. Previously, we synthesized and evaluated a radioiodinated vesamicol derivative, 2-(4-[

Identifiers

PMID36092143
PMCPMC9384704
OpenAlexW4285126181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.